

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 1, 2011

TECHNE CORPORATION
(Exact Name of Registrant as Specified in Charter)

Minnesota 0-17272 41-1427402
(State or Other Jurisdiction (Commission I.R.S. Employer
of Incorporation) File Number) Identification No.)

614 Mckinley Place NE
Minneapolis, MN 55413
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (612) 379-8854

Not Applicable
(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on February 1, 2011, describing the results of operations for the quarter and six months ended December 31, 2010 and its financial condition as of December 31, 2010, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and six months ended December 31, 2010 which has been included on Techne Corporation's website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated February 1, 2011.

99.2 Segment information for the quarter and six months ended December 31, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 1, 2011 TECHNE CORPORATION

By: /s/ Thomas E. Oland

Name: Thomas E. Oland
Title: President and Chief
Executive Officer

EXHIBIT INDEX

Exhibit No. Description

-
- | | |
|------|--|
| 99.1 | Press release of Techne Corporation dated February 1, 2011. |
| 99.2 | Segment information for Techne Corporation for the quarter and six months ended December 31, 2010. |

TECHNE CORPORATION RELEASES UNAUDITED SECOND QUARTER
RESULTS FOR FISCAL YEAR 2011

Minneapolis/February 1, 2011/ Techne Corporation's (NASDAQ: TECH) consolidated net earnings for the quarter ended December 31, 2010 increased 7.3% to \$26.5 million or \$0.71 per diluted share compared with \$24.7 million or \$0.66 per diluted share for the quarter ended December 31, 2009. The increase in consolidated net earnings for the quarter resulted from an increase in sales and a decrease in income taxes due to the renewal of the U.S. research and development credit. The \$898,000 benefit (\$0.02 per share) from the renewal of the research and development credit includes \$659,000 that relates to the previous three calendar quarters. For the six months ended December 31, 2010, Techne's consolidated net earnings increased 2.8% to \$52.9 million or \$1.42 per share compared with \$51.5 million or \$1.38 per share for the six months ended December 31, 2009.

Consolidated net sales for the quarter and six months ended December 31, 2010 were \$67.7 million and \$135.7 million, increases of 3.3% and 2.7%, respectively, from the quarter and six months ended December 31, 2009. Consolidated net sales for the quarter and six months were negatively affected by a stronger U.S. dollar as compared to foreign currencies for the quarter and six months ended December 31, 2009. Excluding the effect of changes in foreign currency exchange rates, consolidated net sales increased 5.1% and 4.5% for the quarter and six months ended December 31, 2010, respectively, from the comparable prior-year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology Division, R&D Systems China and BiosPacific, were \$44.4 million for the quarter ended December 31, 2010, an increase of 4.8% from \$42.4 million for the quarter ended December 31, 2009. North American biotechnology sales to industrial pharmaceutical and biotechnology customers increased 3.9% during the second quarter of fiscal 2011 as compared to the second quarter of fiscal 2010. Biotechnology sales to academic customers and sales in China grew 6.7% and 19.2%, respectively, while sales to Pacific Rim distributors declined 4.5%, in the second quarter of fiscal 2011 as compared to the second quarter of fiscal 2010. Biotechnology sales for the six months ended December 31, 2010, were \$91.1 million, an increase of 5.4% from \$86.4 million for the six months ended December 31, 2009. North American biotechnology sales to industrial pharmaceutical and biotechnology customers increased 3.5% during the six months ended December 31, 2010 as compared to the first six months of fiscal 2010. Biotechnology sales to academic customers, to Pacific Rim distributors, and sales in China grew 8.4%, 1.8% and 16.4%, respectively, in the first six months of fiscal 2011.

R&D Europe's net sales for the quarter and six months ended December 31, 2010 were \$18.6 million and \$35.0 million, decreasing 0.7% and 4.3%, respectively, from the same prior-year periods. R&D Europe's net sales increased 5.5% and 2.2% for the quarter and six months ended December 31, 2010 when measured at currency rates in effect in the comparable prior-year period. Hematology net sales for the quarter and six months ended December 31, 2010 were \$4.6 million and \$9.5 million, increases of 7.0% and 6.0% from the comparable prior-year periods.

Consolidated gross margin for the quarter ended December 31, 2010 increased \$298,000, but decreased \$631,000 for the six months ended December 31, 2010 from the same prior-year periods. Biotechnology gross margin increased \$973,000 and \$1.8 million for the quarter and six months ended December 31, 2010 as a result of increased net sales partially offset by a decrease in gross margin percentage. R&D Europe gross margin decreased \$564,000 and \$2.3 million for the quarter and six months ended December 31, 2010 as compared to the same prior-year periods. Approximately \$1.2 million and \$2.4 million of the decrease in R&D Europe gross margins, respectively, was the result of changes in exchange rates used to translate sales in foreign currencies into U.S. dollars. Approximately 15.0% and 6.4% of consolidated net sales for the six months ended December 31, 2010 were made in euro and British pound sterling, respectively. The average euro exchange rate declined 8.8% and 8.3% against the U.S. dollar for the quarter and six months ended December 31, 2010 (euro:\$1.34 and euro:\$1.33) compared to the same prior-year periods (euro:\$1.47 and euro:\$1.45). The average British pound sterling exchange rate declined 3.7% and 4.3% against the U.S. dollar for the quarter and six months ended December 31, 2010 (British pound:\$1.57 and British pound:\$1.56)

compared to the same prior-year periods (British pound:\$1.63 and British pound:\$1.63). Excluding the effect of the exchange rate on sales, gross margins for R&D Europe increased \$605,000 and \$62,000 for the quarter and six months ended December 31, 2010.

The consolidated gross margin, as a percentage of net sales, was 77.5% for both the quarter and six months ended December 31, 2010, compared to 79.7% and 80.1% for the quarter and six months ended December 31, 2009, respectively. R&D Europe gross margin percentages for the quarter and six months ended December 31, 2010 were 51.2% and 49.4% compared to 53.9% and 53.7%. The decrease was a result of the effect of exchange rate changes on net sales as discussed above. Biotechnology gross margin percentages were 77.8% and 78.1% for the quarter and six months ended December 31, 2010 compared to 80.0% and 80.5% for the quarter and six months ended December 31, 2009. The decrease in the Biotechnology gross margin percentage was mainly the result of changes in product mix and \$220,000 additional royalty expense and royalty initiation fees related to new licensing agreements in the first quarter of fiscal 2011. Royalty initiation fees in the second quarter of fiscal 2011 were not material.

Selling, general and administrative expenses for the quarter and six months ended December 31, 2010 decreased \$642,000 (7.1%) and \$1.1 million (6.6%) from the quarter and six months ended December 31, 2009. The decrease in selling, general and administrative expense for the quarter and six months resulted primarily from decreased legal expenses, lower printing costs due to the timing of the printing of the annual Biotechnology catalog and the effect of the change in exchange rates used to convert foreign expenses to U.S. dollars.

Research and development expenses for the quarter and six months ended December 31, 2010 increased \$212,000 (3.3%) and \$677,000 (5.4%) from the quarter and six months ended December 31, 2009. The increase in research and development expenses is mainly due to increases in personnel and supply costs associated with the continuous development and release of new high-quality biotechnology products.

The effective tax rate for the quarter and six months ended December 31, 2010 was 29.6% and 31.0% as compared to 32.6% for both of the same prior-year periods. The improvement in the effective tax rate in fiscal 2011 was the result of renewal of the U.S. research and development credit discussed above and an increase in the deduction for qualified production activities.

Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning of the Private Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

* * * * *

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific

is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.

Contact: Greg Melsen, Chief Financial Officer
Kathy Backes, Controller
(612) 379-8854

TECHNE CORPORATION
CONSOLIDATED STATEMENTS OF EARNINGS
(In thousands, except per share data)
(Unaudited)

	QUARTER ENDED		SIX MONTHS ENDED	
	12/31/10	12/31/09	12/31/10	12/31/09
Net sales	\$67,708	\$65,521	\$135,653	\$132,055
Cost of sales	15,218	13,329	30,459	26,230
Gross margin	52,490	52,192	105,194	105,825
Operating expenses:				
Selling, general and administrative	8,365	9,007	15,917	17,045
Research and development	6,603	6,391	13,222	12,545
Amortization of intangible assets	171	240	341	480
Total operating expenses	15,139	15,638	29,480	30,070
Operating income	37,351	36,554	75,714	75,755
Other income (expense):				
Interest income	1,020	1,156	1,867	2,324
Other non-operating expense, net	(698)	(1,011)	(955)	(1,673)
Total other (expense) income	322	145	912	651
Earnings before income taxes	37,673	36,699	76,626	76,406
Income taxes	11,139	11,978	23,719	24,913
Net earnings	\$26,534	\$24,721	\$ 52,907	\$ 51,493
Earnings per share:				
Basic	\$ 0.72	\$ 0.66	\$ 1.43	\$ 1.38
Diluted	\$ 0.71	\$ 0.66	\$ 1.42	\$ 1.38
Weighted average common shares outstanding:				
Basic	37,093	37,252	37,066	37,248
Diluted	37,156	37,353	37,131	37,346

TECHNE CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

	12/31/10	6/30/10
ASSETS		
Cash and equivalents	\$135,875	\$ 94,139
Short-term available-for-sale investments	58,987	44,672
Trade accounts receivable	28,228	30,850
Other receivables	1,986	1,532
Inventory	13,736	13,737
Other current assets	14,748	16,110
Current assets	253,560	201,040

Available-for-sale investments	158,666	171,171
Property and equipment, net	95,096	97,400
Goodwill and intangible assets, net	26,771	27,112
Other non-current assets	21,515	22,093

Total assets	<u>-----</u> <u>-----</u> \$555,608	<u>-----</u> <u>-----</u> \$518,816
--------------	--	--

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities	\$ 13,672	\$ 17,024
Stockholders' equity	541,936	501,792

Total liabilities and stockholders' equity	<u>-----</u> <u>-----</u> \$555,608	<u>-----</u> <u>-----</u> \$518,816
--	--	--

SEGMENT INFORMATION
TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of \$'s, except per share data)

	Fiscal 2011		Increase (Decrease) From Fiscal 2010				
	First Qtr.	Second Qtr. YTD	Percent Of Sales	First Qtr.	Second Qtr. YTD		
Sales	67,945	67,708	135,653	100%	1,411	2,187	3,598
Cost of sales	15,241	15,218	30,459	22%	2,340	1,889	4,229
Gross margin	52,704	52,490	105,194	78%	(929)	298	(631)
Gross margin percentage	77.6%	77.5%	77.5%				
SG&A expense	7,552	8,365	15,917	12%	(486)	(642)	(1,128)
R&D expense	6,619	6,603	13,222	10%	465	212	677
Amortization expense	170	171	341	--	(70)	(69)	(139)
Interest income	(847)	(1,020)	(1,867)	(1%)	321	136	457
Other non-operating ex., net	257	698	955	1%	(405)	(313)	(718)
	13,751	14,817	28,568	22%	(175)	(676)	(851)
Earnings before income taxes	38,953	37,673	76,626	56%	(754)	974	220
Income taxes	12,580	11,139	23,719	17%	(355)	(839)	(1,194)
	26,373	26,534	52,907	39%	(399)	1,813	1,414
Diluted earnings per share	0.71	0.71					
Weighted average diluted shares outstanding	37,107	37,156					

BIOTECHNOLOGY (1)
(in thousands of \$'s)

	Fiscal 2011		Increase (Decrease) From Fiscal 2010				
	First Qtr.	Second Qtr. YTD	Percent Of Sales	First Qtr.	Second Qtr. YTD		
Sales	54,141	52,652	106,793	100%	2,445	1,949	4,394
Intersegment sales	(7,491)	(8,217)	(15,708)		177	65	242
	46,650	44,435	91,085		2,622	2,014	4,636
Cost of sales	11,689	11,665	23,354	22%	1,804	1,539	3,343
Intersegment sales	(7,578)	(8,251)	(15,829)		20	(498)	(478)
	4,111	3,414	7,525		1,824	1,041	2,865
Gross margin	42,539	41,021	83,560	78%	798	973	1,771
Gross margin percentage	78.4%	77.8%	78.1%				
SG&A expense	4,583	4,780	9,363	9%	(151)	(276)	(427)
R&D expense	6,421	6,379	12,800	12%	465	189	654
Amortization expense	170	171	341	--	(70)	(69)	(139)
Interest income	(581)	(715)	(1,296)	(1%)	190	57	247
Exchange loss/gain	(8)	(10)	(18)	--	(10)	(11)	(21)

	10,585	10,605	21,190	20%	424	(110)	314
Pretax result	31,954	30,416	62,370	58%	374	1,083	1,457

(1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc. and R&D China

R&D SYSTEMS EUROPE
(in thousands of Br. pounds)

	Fiscal 2011		Increase (Decrease) From Fiscal 2010				
	First Qtr.	Second Qtr. YTD	Percent Of Sales	First Qtr.	Second Qtr.	YTD	
Sales	10,571	11,767	22,338	100%	(310)	305	(5)
Cost of sales	5,561	5,742	11,303	51%	500	454	954
Gross margin	5,010	6,025	11,035	49%	(810)	(149)	(959)
Gross margin percentage	47.4%	51.2%	49.4%				
SG&A expense	1,188	1,274	2,462	11%	(3)	(44)	(47)
Interest income	(52)	(65)	(117)	(1%)	35	14	49
Exchange loss/(gain)	(323)	58	(265)	(1%)	(234)	(3)	(237)
	813	1,267	2,080	9%	(202)	(33)	(235)
Pretax result	4,197	4,758	8,955	40%	(608)	(116)	(724)

R&D SYSTEMS EUROPE
(in thousands of \$'s)

	Fiscal 2011		Increase (Decrease) From Fiscal 2010				
	First Qtr.	Second Qtr. YTD	Percent Of Sales	First Qtr.	Second Qtr.	YTD	
Sales	16,391	18,645	35,036	100%	(1,447)	(130)	(1,577)
Cost of sales	8,621	9,097	17,718	51%	326	433	759
Gross margin	7,770	9,548	17,318	49%	(1,773)	(563)	(2,336)
Gross margin percentage	47.4%	51.2%	49.4%				
SG&A expense	1,842	2,017	3,859	11%	(110)	(142)	(252)
Interest income	(81)	(103)	(184)	(1%)	62	25	87
Exchange loss/(gain)	(497)	97	(400)	(1%)	(352)	(2)	(354)
	1,264	2,011	3,275	9%	(400)	(119)	(519)
Pretax result	6,506	7,537	14,043	40%	(1,373)	(444)	(1,817)

HEMATOLOGY
(in thousands of \$'s)

	Fiscal 2011		Increase (Decrease) From Fiscal 2010				
	First Qtr.	Second Qtr. YTD	Percent Of Sales	First Qtr.	Second Qtr.	YTD	

Sales	4,904	4,628	9,532	100%	236	303	539
Cost of sales	2,509	2,707	5,216	55%	190	415	605
Gross margin	2,395	1,921	4,316	45%	46	(112)	(66)
Gross margin percentage	48.8%	41.5%	45.3%				
SG&A expense	328	336	664	7%	(42)	(30)	(72)
R&D expense	198	224	422	4%	--	23	23
Interest income	(53)	(66)	(119)	(1%)	19	6	25
	473	494	967	10%	(23)	(1)	(24)
Pretax result	1,922	1,427	3,349	35%	69	(111)	(42)

CORPORATE AND OTHER (2)
(in thousands of \$'s)

	Increase (Decrease)					
	Fiscal 2011		From Fiscal 2010			
	First Qtr.	Second Qtr.	YTD	First Qtr.	Second Qtr.	YTD
Interest income	132	136	268	(50)	(48)	(98)
Rental income	123	138	261	42	23	65
	255	274	529	(8)	(25)	(33)
SG&A expense	799	1,232	2,031	(183)	(194)	(377)
Other-Building expenses	556	531	1,087	8	1	9
Other-Equity Investment losses	329	218	547	(9)	(278)	(287)
	1,684	1,981	3,665	(184)	(471)	(655)
Pretax result	(1,429)	(1,707)	(3,136)	176	446	622

(2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC and Nephromics, LLC.